Main content

    Liver Transplant / Hepatology / Hepatitis / Liver Failure Clinical Trials

    Liver Disease Management & Transplant Program

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Liver Failure including Acute Liver Injury  |  Thrombocytopenia  |  Hepatitis B  |  Hepatitis C  |  Co-infection (HCV & HIV)  |  Drug and CAM Induced Liver Injury  |  Hepatoma


    Active Trials

    Liver Failure including Acute Liver Injury

    Title: A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure
    Decscription: The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function
    Investigator: Todd Frederick, MD
    Eligibility: Subjects 18 years of age and older with a clinical, radiological and/or histological diagnosis of cirrhosis
    Status: Active and open to enrollment
    Contact: Anna von Bakonyi, LVN, 415-600-1107, Email: vonBakA@cpmcri.org about Study Conatus

    Title: A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
    Decscription: This study is to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18
    Investigator: Todd Frederick, MD
    Eligibility: Subjects 18 years of age and older with clinical, radiological, or biochemical evidence of liver cirrhosis
    Status: Active and open to enrollment
    Contact: Anna von Bakonyi, LVN, 415-600-1107, Email: vonBakA@cpmcri.org about Study Conatus Cirrhosis

    Title: Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study
    Decscription: The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, who are hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis
    Status: Active and open to enrollment
    Contact: Anna von Bakonyi, LVN, 415-600-1107, Email: vonBakA@cpmcri.org about Study Ocera STOP-HE

    Back to top

    Thrombocytopenia

    Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure
    Decscription: Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
    Investigator: Maurizio Bonacini, MD
    Eligibility: Subjects, 18 y/o and older, with chronic liver disease scheduled to undergo a permitted elective procedure who, in the opinion of the investigator, will require a platelet transfusion to address a risk of bleeding associated with the procedure
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study Eisai 311

    Back to top

    Hepatitis B

    Title: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B
    Decscription: This clinical trial compares the efficacy of peginterferon plus tenofovir for 24 weeks followed by monotherapy with tenofovir for a further 3.5 years to the efficacy of tenofovir alone given for 4 years in patients with chronic hepatitis B. The primary measure of outcome will be HBsAg loss in serum at 48 weeks after stopping all antiviral therapy (sustained off-treatment response)
    Investigator: Stewart Cooper, MD
    Eligibility: Subjects 18 years and older with chronic hepatitis B invection
    Status: Active and open to enrollment
    Contact: Veronika Podolskaya, 415-600-1102, Email: PodolsV@cpmcri.org about Study HBRN Immune Active

    Title: Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study)
    Decscription: this study is to describe participants with hepatitis B virus (HBV) infection and identify factors that may cause the disease to activate or worsen
    Investigator: Stewart Cooper, MD
    Eligibility: Subjects 18 years and older with chronic Hepatitis B
    Status: Active and open to enrollment
    Contact: Veronika Podolskaya, 415-600-1102, Email: PodolsV@cpmcri.org about Study Cohort study

    Title: Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
    Decscription: This study is to evaluate the safety and efficacy of a short lead-in course (8 weeks) of entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks. The investigators hypothesize that using a potent nucleos(t)ide analogue will provide a higher rate of loss of HBeAg loss and suppression of HBV DNA
    Investigator: Stewart Cooper, MD
    Eligibility: Subjects 18 years of age and older with chronic Hepatitis B infection
    Status: Active and open to enrollment
    Contact: Veronika Podolskaya, 415-600-1102, Email: PodolsV@cpmcri.org about Study HBRN IT Adult Trial

    Back to top

    Hepatitis C

    Title: An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
    Decscription: The purpose of this study is to evaluate Long-term Outcomes following treatment with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
    Investigator: Maurizio Bonacini, MD
    Eligibility: Subjects 18 years of age and older with chronic hepatitis C, genotype 1-infection (HCV RNA level greater than 1,000 IU/mL at screening)
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study TOPAZ II

    Title: An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ┬▒ Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study
    Decscription: This is an open label study that will investigate the safety, tolerability and antiviral efficacy of SOF/LDV with or without RBV for 12 or 24 weeks in chronic genotype 1 HCV infected subjects that failed prior treatment in a previous Gilead-sponsored HCV treatment study
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, with HCV genotype 1 who have participated in a previous Gilead-sponsored HCV study
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study GS-1118

    Back to top

    Co-infection (HCV & HIV)


    Currently there are no Clinical Research Studies for HCV and HIC Co-infection. Please check back at a later date as we are always adding new studies.

    Back to top

    Drug and CAM Induced Liver Injury


    Currently there are no Clinical Research Studies for Drug and CAM Induced Liver Injury. Please check back at a later date as we are always adding new studies.

    Back to top

    Hepatoma

    Please click here to see our Hepatoma clinical trials.


    • updated October 2014

    Back to top